When options matter. Vasopressor Reloaded. Balance in Haemodynamics - Only Survival Matters
|
|
- Cora Ray
- 5 years ago
- Views:
Transcription
1 When options matter Vasopressor Reloaded Balance in Haemodynamics - Only Survival Matters
2 Vasopressin Synthesis and Release Physiologic Importance in Septic Shock Hypothalamus Brain Vasopressin deficiency contributes to vasodilation of septic shock 5 v1-receptor Vasopressin into circulation Pituitary Renal V 2 receptors: AH 2 O permeability in collecting duct retain H 2 O Secretion triggers: A Osmolality G Plasma Volume A Angiotensin II Vascular V1 receptors: A Aterial BP Hypothalamus Plasma Vasopressin Level (pg/ml) 2 1 Normal Early Late Septic Shock Vasopressin- Defizit Vasoconstriction v2-receptor Water retention in the kidney v3 (v1b)-receptor Vasopressin (synonyma: argipressin, arginin vasopressin, antidiuretic hormone) is a small neurohypophysial hormone, synthesized in the hypothalamus and stored in the posterior pituitary gland. It is made as part of a larger precursor molecule. Cleavage leads to release of vasopressin, neurophysin II and copeptin. 1 The main stimuli for vasopressin release from its storage granules are increased plasma osmolality and decreased plasma volume, as for example in hemodynamic changes. 2 After release into the bloodstream, vasopressin can exert its anti-diuretic and vasoconstrictive actions via V2 (renal) and V1 (vascular) receptors. 1 In septic shock, relative vasopressin deficiency has been reported. 3 After an initial rise of circulating vasopressin, levels fall significantly within hours without returning to basal values. This phenomenon might be due to depletion of stored vasopressin as well as inhibition of new vasopressin synthesis and release within the hypothalamus and pituitary. 4 Vasopressin plasma levels therefore are sub-optimally low during septic shock, which contributes to hypotension. 5 This explains the rationale for adding low dose vasopressin to substantially improve patient management in this life-threatening condition. 5 ACTH AVP Endocrine cells release ACTH into the circulation which stimulates cortisol release from the adrenal gland 2 3
3 Vasopressin: Increasing Mean Arterial Pressure And Decreasing Norepinephrine in Septic Shock Vasopressin added to norepinephrine increases MAP significantly 6 Vasopressin is associated with a norepinephrine sparing effect 8 MAP mmhg Surviving Sepsis Campaign Guidelines 7 International Guidelines for Management of Sepsis and Septic Shock: 2016 Vasopressin (up to 0.03 IU/min) can be added to norepinephrine with the intent of raising MAP or decreasing norepinephrine dosage NE 0h 1h 12h 24h 48h p<0.001 VA/NE Rate of all norepinephrine infusions (mg/min, median + IQR) Rate of NE in the norepinephrine-treated group Rate of NE in the vasopressin-treated group VASST Trial Time from study drug infusion (days) Vasopressor therapy targets a MAP of 65 mmhg. 7 With vasopressin the target MAP is achieved while saving Norepinephrine. 8 p<
4 Norepinephrine Not Too Much, Not Too Long Norepinephrine Causes Tachyarrhythmia 10 Mortality in septic shock increases with the dose of norepinephrine 9 Mortality is higher in septic shock patients with increasing norepinephrine requirements and tachycardia % Patients dying during NE-infusion % Patients dying after cessation of NE-infusion 28 day mortality (%) in patients with different dosage of norepinephrine Heart Rate 95 bpm < 95 bpm Death Rate (percentage) ( ) ( ) ( ) (0.64-1) [1 10] 2 Range of norepinephrine dosage (mcg/kg/min) < >0.3 p<0.01 mcg/kg/min NE Heart rate measured 24h after initiation of norepinephrine therapy 11 A threshold of 0.5 mcg/kg/min NE is associated with > 2x increase of mortality. A dosage greater than 1 mcg/kg/min is associated with a death rate greater than 90%. 9 Catecholamine vasopressor therapy is associated with incidence of tachyarrhythmia, elevated heart rate and myocardial cell damage
5 Better Outcome with Vasopressin in Less Severe Septic Shock VASST-Study: significantly higher probability of survival with vasopressin in less severe septic shock patients 8,17 Better Survival in Patients at Renal Risk VASST-Study: patients at risk for renal failure according to RIFLE criteria* with vasopressin added 12 Probability of survival (%) Catecholamine vasopressors + Vasopressin (28 day mortality 26.5%) + Norepinephrine (28 day mortality 35.7%) Days since initiation of study drug p=0.05 day 28 p=0.03 day 90 Probability of survival (%) No. Patients (%) Catecholamine vasopressors + Vasopressin Catecholamine vasopressors + Vasopressin + Norepinephrine p= Days from study inclusion No. Patients (%) Catecholamine vasopressors + Norepinephrine Need for RRT during 28-day 9/ % 20/ % 0.02 P-value * Rifle Criteria Risk patients : Increased serum creatinine x 1.5 In the VASST study 378 less severe septic shock patients defined as treatment < 15μg / min Norepinephrine at randomization had better survival rate at 28 and 90 days when Vasopressin was added. 8 VASST-Study: patients at risk of renal failure* had significantly better survival rate and less need for renal replacement therapy (RRT) when vasopressin was added
6 Early Vasopressin Reduces Incidence of New Onset Arrhythmias Low Lactate Predictive of Beneficial Response to Vasopressin Less new onset of rapid atrial fibrillation or ventricular tachycardia 13 VASST-Study: patients with low lactate (< 1.4 mmol/l) show beneficial response to vasopressin versus norepinephrine Late Vasopressin added after 6h up to 48h Early Vasopressin added within 6h n=23/36 n=13/ % 62.9% Probability of mortality (%) lactate 1.4 mmol/l Catecholamine vasopressors + Vasopressin (n=90) + Norepinephrine (n=77) p<0.001 Onset of rapid atrial fibrillation / ventricular tachycardia Days p<0.05 In septic shock, when vasopressin was added early within 6h of catecholamine initiation, it was associated with a significantly decreased incidence of new onset arrhythmias*. 13 Survival curves comparing vasopressin added to norepinephrine (NE) versus sole norepinephrine in patients with lactate level 1.4 mmol/l show significant beneficial response to vasopressin. 14 *New onset arrhythmia was defined as rapid atrial fibrillation (>160 beats per minute) or ventricular tachycardia in a patient without a documented history of that arrhythmia 10 11
7 Vasopressin in Patients with Pulmonary Hypertension Recommendations Empressin Therapy in Septic Shock Vasopressin does not effect 15, 18, 19 pulmonary vascular tone Empressin is indicated for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years Human pulmonary arteries A catecholamine refractory hypotension is present if the mean arterial blood pressure cannot be stabilized to target despite adequate volume substitution and application of catecholamines. 16 %KPSS maximum Drug concentration log M Vasopressin Norepinephrine Phenylephrine Empressin (up to 0.03 IU/min) can be added to norepinephrine with the intent of raising MAP or decreasing NE dosage 7 Mortality rate in septic shock increases with an increase in norepinephrine dose. 9 Therefore Empressin added to NE should be used in less severe septic shock patients* with the intent of decreasing NE. 8,17 *Defined as patients with treatment NE<15 μg/min (~0.214mcg/kg/min in case of body weight 70kg) In contrast to catecholamine-based vasopressor agents such as norepinephrine or phenylephrine, vasopressin does not constrict pulmonary arteries. This supports the use of vasopressin 15, 18, 19 in patients with pulmonary hypertension. Empressin added to norepinephrine should be used - early in patients at risk for renal failure* 12 - within first 6h after start of catecholamine vasopressors 13 - prior to increase of serum lactate >2mmol/L 14 * RIFLE criteria risk : increased serum creatinine x
8 Empressin Dosage Recommendation 16 References Empressin dose up to 0.03 IU/min can be added to norepinephrine with the intent of increasing MAP to target, or decrease norepinephrine dosage 7 Increase dose every minutes Dose Empressin /min Dosage Empressin 40 I.U./ 2 ml solution for injection (= one ampoule) Prepare a solution for infusion by diluting 2 ml of the concentrate with 48 ml of Sodium chloride 9 mg/ml (0.9%) solution (equivalent to 0.8 I.U. argipressin per ml). The total volume after dilution should be 50 ml. Titration dose 0.01 I.U. Empressin per minute (syringe pump) Dose Empressin /hour The usual mean arterial pressure (MAP) target in intensive care patients is > 65 mmhg up to 0.03 I.U. per minute (Doses above 0.03 I.U. per minute should only be applied as an emergency treatment.) Infusion rate 0.01 I.U. 0.6 I.U ml / hour 0.02 I.U. 1.2 I.U ml / hour 0.03 I.U. 1.8 I.U ml / hour 1 Holt NF et al.: Vasopressin: a review of therapeutic applications. J Cardiothorac Vasc Anesth 2010; 24(2): Morgenthaler NG et al.: Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28(2): Sharshar T et al.: Circulating vasopressin levels in septic shock. Crit Care Med 2003; 31(6): Sharshar T et al.: Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002; 30(3): Landry DW et al.: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: Dünser M.W.: Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study; Circulation May 13;107(18): Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R.,... & Rochwerg, B. (2017). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: Intensive care medicine, 43(3), Russell JA : Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care. 2011; 15(226): Martin C et al.: Norepinephrine: Not Too Much, too long; Shock 2015 Oct;44(4): Schmittinger CA et al.: Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med.2012;38(6): Domizi R. & al. «Relationship between catecholamine dose, tachycardia and outcome in septic shock: A multicentre evaluation» ESICM, 2014,abstract 12 Gordon A.C. et al.: The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010; 36: Reardon DP et al.: Early vasopressin reduces incidence of new onset arrhythmias. J Crit Care 2014 ;29(4): Wacharasint P et al.: Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock 2012;38(1): Currigan DA et al.: Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries. Anesthesiology 2014; 121: Summary of Product Characteristics, current version 17 Russel JA: Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. N Engl J Med 2008; 358: Chan C et al.: Sepsis and Pulmonary Arterial Hypertension in the ICU. Advances in Pulmonary Hypertension.2015;13:4: Holmes CL et al.: Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology. Crit Care Feb;8(1):15-23 NAME OF THE MEDICINAL PRODUCT: Empressin 40 I.U./2 ml concentrate for solution for infusion QUALITATIVE AND QUANTITATIVE COMPOSITION: One ampoule with 2 ml concentrate for solution for infusion contains argipressin acetate corresponding to 40 I.U. argipressin (equating 133 microgram). 1 ml concentrate for solution for infusion contains argipressin acetate corresponding to 20 I.U. argipressin (equating 66.5 microgram). Excipients with known effect: Each ml contains less than 23 mg of sodium. List of excipients: Sodium chloride, glacial acetic acid or ph adjustment, water for injections. Therapeutic indications: Empressin is indicated for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressure cannot be stabilised to target despite adequate volume substitution and application of catecholamines (see section 5.1 of the published SmPC). Pharmacotherapeutic group: Vasopressin and analogues, ATC code: H01BA01 Contraindications: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the published SmPC. Nature and contents of container: Clear glass ampoules (Type I, with a broken ring on the narrow part of the ampoule) with 2 ml concentrate for solution for infusion. Pack sizes: 5 and 10 ampoules. Not all pack-sizes may be marketed. MARKETING AUTHORISATION HOLDER: Orpha-Devel Handels und Vertriebs GmbH, Wintergasse 85/1B, 3002 Purkersdorf, Austria DATE OF REVISION OF THE TEXT: 02 / 2018 Prescription status/ Delivery by pharmacies: Prescription only medicine/ Pharmacy-only For information on undesirable effects, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, use in pregnancy and lactation and impact on fertility please refer to the published SmPC
9 VAS049_0518INT When options matter Increase chances of survival by using in early septic shock 8 Ensure haemodynamic stabilization by reversing vasopressin deficiency 5 Balance norepinephrine toxicity by enabling decatecholaminization 8 Medicine when it matters most
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK. Alexandria Rydz
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK Alexandria Rydz BACKGROUND- SEPSIS Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated
More informationVOLUME RESPONSIVENESS IS DIFFERENT FROM NEED FOR FLUIDS BLOOD PRESSURE TARGETS IN SEPSIS
Department of Intensive Care Medicine VOLUME RESPONSIVENESS IS DIFFERENT FROM NEED FOR FLUIDS BLOOD PRESSURE TARGETS IN SEPSIS SEPTIC SHOCK : THE CLINICAL SCENARIO HYPOTENSION DESPITE ADEQUATE VOLUME RESUSCITATION
More informationShould we use steroids in sepsis? J.G. van der Hoeven
Should we use steroids in sepsis? J.G. van der Hoeven Why I don t like it It is boring.. It usually results in emotional outcries in the audience If any, the effects on outcome are very small You are not
More informationWhen Fluids are Not Enough: Inopressor Therapy
When Fluids are Not Enough: Inopressor Therapy Problems in Neonatology Neonatal problem: hypoperfusion Severe sepsis Hallmark of septic shock Secondary to neonatal encephalopathy Vasoplegia Syndrome??
More informationControversies in Hospital Medicine: Critical Care. Vasopressors, Steroids, and Insulin Therapy
Controversies in Hospital Medicine: Critical Care Vasopressors, Steroids, and Insulin Therapy Douglas Fish, Pharm.D. Professor of Pharmacy, University of Colorado Denver Clinical Specialist in Critical
More informationTitrating Critical Care Medications
Titrating Critical Care Medications Chad Johnson, MSN (NED), RN, CNCC(C), CNS-cc Clinical Nurse Specialist: Critical Care and Neurosurgical Services E-mail: johnsoc@tbh.net Copyright 2017 1 Learning Objectives
More information(angiotensin II) injection for intravenous infusion
ADMINISTERING GIAPREZA TM (angiotensin II) injection for intravenous infusion Visit www.giapreza.com INITIATE Recommended starting dose of GIAPREZA is 20 ng/kg/min, which is equivalent to 0.02 mcg/kg/min
More information*Sections or subsections omitted from the full prescribing information are not listed.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GIAPREZA TM safely and effectively. See full prescribing information for GIAPREZA. GIAPREZA (angiotensin
More informationEfficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock
669163AOPXXX10.1177/1060028016669163Annals of PharmacotherapyWu et al research-article2016 Research Report Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock Annals of Pharmacotherapy
More informationVasopressors in Septic Shock. Keith R. Walley, MD St. Paul s Hospital University of British Columbia Vancouver, Canada
Vasopressors in Septic Shock Keith R. Walley, MD St. Paul s Hospital University of British Columbia Vancouver, Canada Echocardiogram: EF=25% 57 y.o. female, pneumonia, shock Echocardiogram: EF=25% 57 y.o.
More informationEvidence-Based. Management of Severe Sepsis. What is the BP Target?
Evidence-Based Management of Severe Sepsis Michael A. Gropper, MD, PhD Professor and Vice Chair of Anesthesia Director, Critical Care Medicine Chair, Quality Improvment University of California San Francisco
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each ml solution for injection contains phenylephrine hydrochloride corresponding to 0.1 mg phenylephrine.
1. NAME OF THE MEDICINAL PRODUCT Fenylefrin Abcur 0.05 mg/ml, solution for injection Fenylefrin Abcur 0.1 mg/ml, solution for injection SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone
PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Perfan Injection 100 mg/20 ml Concentrate for Solution for Injection Active substance: enoximone Read all of this leaflet carefully before you
More informationVasopressors in septic shock
Vasopressors in septic shock Prof. Jean-Louis TEBOUL Medical ICU Bicetre hospital University Paris-South France Questions 1- Why do we use vasopressors in septic shock? 2- Which first-line agent? 3- When
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More information4/5/2018. Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY. I have no financial disclosures
Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY I have no financial disclosures 1 Objectives Why do we care about sepsis Understanding the core measures by Centers for Medicare
More informationShould Roids Be the Rage in Septic Shock? Lauren Powell, MSN, RN, CCRN, AGACNP-BC CHI Baylor St. Luke s Medical Center, Houston, TX
Should Roids Be the Rage in Septic Shock? Lauren Powell, MSN, RN, CCRN, AGACNP-BC CHI Baylor St. Luke s Medical Center, Houston, TX Learning Objectives 1. Review the mechanism of action for the use of
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Albuman 40 g/l is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albuman 40 g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albuman 40 g/l is a solution containing 40 g/l (4%)
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Albunorm 5%, 50 g/l, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 5% is a solution containing 50 g/l of total
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS PRODUCT SUMMARY 1. NAME OF THE MEDICINAL PRODUCT Sterile Potassium Chloride Concentrate 15%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 15% of Potassium Chloride in
More informationCORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE
CORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE 1 ABBREVIATIONS ACCP = American College of Chest Physicians ARF =
More informationCase year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50
Case 1 65 year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50 Case 1 65 year old female nursing home resident with
More informationSepsis is a complicated infectious process that propagates. Use of Vasopressors in Septic Shock. Clinical review
Use of Vasopressors in Septic Shock Megan A. Rech, PharmD, Megan Prasse, PharmD, and Gourang Patel, PharmD, MSc Abstract Objective: To review the latest findings on the use of vasopressor agents in septic
More informationMaking vasopressors safer
Making vasopressors safer Requirements for safe vaspressor use In an ideal world 1. Knowledge of what constitutes optimal vasopressor dosing 2. A culture of cautiousness regarding vasopressors What do
More information3. PHARMACEUTICAL FORM Solution for infusion. A clear, slightly viscous liquid; it is almost colourless, yellow, amber or green.
1. NAME OF THE MEDICINAL PRODUCT Albutein 250 g/l, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human albumin Albutein 250 g/l is a solution containing 250 g/l of total protein of
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Addaven concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Addaven contains: 1 ml 1 ampoule (10 ml) Chromic
More informationFew clinical trials have directly
CLNCAL CONSULTATON CLNCAL CONSULTATON for vasopressor-dependent septic shock PAUL M. SZUMTA, CHRSTOPHER M. ENFANTO, BONNE GREENWOO, AN MCHAEL E. WECHSLER The Clinical Consultation column provides brief
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Albunorm 20%, 200 g/l, solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 20% is a solution containing 200 g/l
More informationProtamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion.
1. NAME OF THE MEDICINAL PRODUCT Protamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Protamine sulphate 1400 anti-heparin
More informationThe Art and Science of Infusion Nursing John M. Allen, PharmD, BCPS. Understanding Vasoactive Medications
The Art and Science of Infusion Nursing John M. Allen, PharmD, BCPS Understanding Vasoactive Medications Focus on Pharmacology and Effective Titration ABSTRACT In the care of the critically ill patient,
More informationINTENSIVE CARE MEDICINE CPD EVENING. Dr Alastair Morgan Wednesday 13 th September 2017
INTENSIVE CARE MEDICINE CPD EVENING Dr Alastair Morgan Wednesday 13 th September 2017 WHAT IS NEW IN ICU? (RELEVANT TO ANAESTHETISTS) Not much! SURVIVING SEPSIS How many deaths in England were thought
More informationHormonal Control of Osmoregulatory Functions *
OpenStax-CNX module: m44828 1 Hormonal Control of Osmoregulatory Functions * OpenStax This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 3.0 By the end of
More informationCardiovascular Management of Septic Shock
Cardiovascular Management of Septic Shock R. Phillip Dellinger, MD Professor of Medicine Robert Wood Johnson Medical School/UMDNJ Director, Critical Care Medicine and Med/Surg ICU Cooper University Hospital
More informationHuman Albumin 200 g/l Baxter is a solution containing 200 g/l of total protein of which at least 95% is human albumin.
1. NAME OF THE MEDICINAL PRODUCT Human Albumin 200 g/l Baxter Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human Albumin 200 g/l Baxter is a solution containing 200 g/l of total protein
More informationNorepinephrine (Levophed )
Norepinephrine (Levophed ) Scope C3IFT CCT Generic Name: Norepinephrine Trade Name: Levophed Chemical Class: Therapeutic Class: Actions: Pharmacokinetics: Vasopressor Vasopressor Mechanism of Action: Norepinephrine
More informationCOMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)
COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH) HUMAN ALBUMIN 20 % BEHRING Rev.: 05-MAR-2008 / PEI approval 26.02.08 Supersedes previous versions Rev.: 28-NOV-2007 / Adaptation to Core SPC Rev.: 02-JAN-2007
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Flexbumin 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Flexbumin 200g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Flexbumin 200 g/l is a solution containing 200 g/l
More informationWhen Fluids are Not Enough: Inopressor Therapy
When Fluids are Not Enough: Inopressor Therapy Problems in Neonatology Neonatal problem: hypoperfusion Severe sepsis Hallmark of septic shock Secondary to neonatal encephalopathy Vasoplegia Syndrome??
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Alburex 5, 50 g/l, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Alburex 5 is a solution containing 50 g/l of total
More information(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS
albunorm TM 5% (human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS UK IRELAND and Ireland Octapharma Limited The Zenith Building, 26 Spring Gardens Manchester M2 1AB United Kingdom 1. Name
More informationVasopressor hormones in shock noradrenaline, vasopressin or angiotensin II: which one will make the race?
Editorial Vasopressor hormones in shock noradrenaline, vasopressin or angiotensin II: which one will make the race? Martin W. Dünser 1, Jens Meier 2 1 Department of Critical Care, University College of
More information(human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS
albunorm TM 20% (human albumin solution) POM SUMMARY OF PRODUCT CHARACTERISTICS UK IRELAND and Ireland Octapharma Limited The Zenith Building, 26 Spring Gardens Manchester M2 1AB United Kingdom 1. Name
More informationBIPN100 F15 Human Physiology (Kristan) Lecture 18: Endocrine control of renal function. p. 1
BIPN100 F15 Human Physiology (Kristan) Lecture 18: Endocrine control of renal function. p. 1 Terms you should understand by the end of this section: diuresis, antidiuresis, osmoreceptors, atrial stretch
More informationObjectives. Pathophysiology of Steroids. Question 1. Pathophysiology 3/1/2010. Steroids in Septic Shock: An Update
Objectives : An Update Michael W. Perry PharmD, BCPS PGY2 Critical Care Resident Palmetto Health Richland Hospital Review the history of steroids in sepsis Summarize the current guidelines for steroids
More informationVasoactive Medications. Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis
Vasoactive Medications Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis Objectives List components of physiology involved in blood pressure Review terminology related
More informationSepsis: Identification and Management in an Acute Care Setting
Sepsis: Identification and Management in an Acute Care Setting Dr. Barbara M. Mills DNP Director Rapid Response Team/ Code Resuscitation Stony Brook University Medical Center SEPSIS LECTURE NPA 2018 OBJECTIVES
More informationNeosynephrine. Name of the Medicine
Name of the Medicine Neosynephrine Phenylephrine hydrochloride 1% injection Neosynephrine Presentation Neosynephrine is a clear, colourless, aqueous solution, free from visible particulates, in sterile
More informationAdenosine. poison/drug induced. flushing, chest pain, transient asystole. Precautions: tachycardia. fibrillation, atrial flutter. Indications: or VT
Adenosine Indications: 1. Narrow complex PSVT 2. Does not convert atrial fibrillation, atrial flutter or VT 1. Side effects include flushing, chest pain, transient asystole 2. May deteriorate widecomplex
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albunorm 20%, 200g/l, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albunorm 20% is a solution containing 200 g/l
More informationHypotension in the Neonate
Neonatal Nursing Education Brief: Hypotension in the Neonate http://www.seattlechildrens.org/healthcare-professionals/education/continuing-medicalnursing-education/neonatal-nursing-education-briefs/ Neonatal
More informationMechanism: 1- waterretention from the last part of the nephron which increases blood volume, venous return EDV, stroke volume and cardiac output.
Blood pressure regulators: 1- Short term regulation:nervous system Occurs Within secondsof the change in BP (they are short term because after a while (2-3 days) they adapt/reset the new blood pressure
More informationBlood Pressure Fox Chapter 14 part 2
Vert Phys PCB3743 Blood Pressure Fox Chapter 14 part 2 T. Houpt, Ph.D. 1 Cardiac Output and Blood Pressure How to Measure Blood Pressure Contribution of vascular resistance to blood pressure Cardiovascular
More informationTaiwan Crit. Care Med.2009;10: C 1. CVP 8~12 mmhg 2. MAP 65 mmhg 1. 1B
6 24 1C 1. CVP 8~12 mmhg 2. MAP 65 mmhg 3. 0.5 ml 4. 70% 65% 1 colloid crystalloid 1B SAFE albumin 2 813 386 07-346-8278 07-350-5220 E-mail shoalin01@.gmail.com 21 p=0.09 prospective meta-analysis 3-5
More informationACETYLCYSTEINE INJECTION
ACETYLCYSTEINE INJECTION 1. Name of the medicinal product Acetylcysteine 200 mg/ml Injection 2. Qualitative and quantitative composition Acetylcysteine 200mg per ml (as N-acetylcysteine) Each 10ml ampoule
More informationIntroduction. Invasive Hemodynamic Monitoring. Determinants of Cardiovascular Function. Cardiovascular System. Hemodynamic Monitoring
Introduction Invasive Hemodynamic Monitoring Audis Bethea, Pharm.D. Assistant Professor Therapeutics IV January 21, 2004 Hemodynamic monitoring is necessary to assess and manage shock Information obtained
More informationPredictors of response to fixed dose vasopressin in adult patients with septic shock
https://doi.org/10.1186/s13613-018-0379-5 RESEARCH Open Access Predictors of response to fixed dose vasopressin in adult patients with septic shock Gretchen L. Sacha 1*, Simon W. Lam 1, Abhijit Duggal
More informationActualités de la prise en charge hémodynamique initiale Daniel De Backer
Actualités de la prise en charge hémodynamique initiale Daniel De Backer Head Dept Intensive Care, CHIREC hospitals, Belgium Professor of Intensive Care, Université Libre de Bruxelles Past- President European
More informationBlockage of Arginine Vasopressin Receptor 2 Reduces Increase in Pulmonary Vascular Resistance in Ovine Sepsis Model
Blockage of Arginine Vasopressin Receptor 2 Reduces Increase in Pulmonary Vascular Resistance in Ovine Sepsis Model Ernesto Lopez MD 1 Osamu Fujiwara MD 1, Baigalmaa Enkhtaivan MD 1, Jose Rojas PhD 2,
More informationVamin 18 EF QUALITATIVE AND QUANTITATIVE COMPOSITION
Title Page Information Dec. 2000 1 (7) Number Vamin 18 EF 121-01 1. NAME OF THE MEDICINAL PRODUCT Vamin 18 g N/l electrolyte-free infusion fluid, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1000
More informationSpecial Lecture 11/08/2013. Hypertension Dr. HN Mayrovitz
Special Lecture 11/08/2013 Hypertension Dr. HN Mayrovitz Arterial Blood Pressure (ABP) Major Factors Summarized Sympathetic Hormones Arteriole MAP ~ Q x TPR + f (V / C) SV x HR Renal SBP Hypertension =
More informationPhysiological Response to Hypovolemic Shock Dr Khwaja Mohammed Amir MD Assistant Professor(Physiology) Objectives At the end of the session the
Physiological Response to Hypovolemic Shock Dr Khwaja Mohammed Amir MD Assistant Professor(Physiology) Objectives At the end of the session the students should be able to: List causes of shock including
More informationUpdate in Critical Care Medicine
Update in Critical Care Medicine Michael A. Gropper, MD, PhD Professor and Executive Vice Chair Department of Anesthesia and Perioperative Care Director, Critical Care Medicine UCSF Disclosure None Update
More informationThe Pharmacology of Hypotension: Vasopressor Choices for HIE patients. Keliana O Mara, PharmD August 4, 2018
The Pharmacology of Hypotension: Vasopressor Choices for HIE patients Keliana O Mara, PharmD August 4, 2018 Objectives Review the pathophysiology of hypotension in neonates Discuss the role of vasopressors
More informationJMSCR Vol 05 Issue 02 Page February 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i2.166 Vasopressin and Terlipressin for Pediatric
More informationMANAGEMENT OF CIRCULATORY FAILURE
MANAGEMENT OF CIRCULATORY FAILURE BACKGROUND AND DEFINITION There is no consensus on the definition of circulatory failure or shock in newborns; it can be defined as global tissue hypoxia secondary to
More informationVasopressors for shock
Vasopressors for shock Background Reviews and Observational Studies Holler 2015. Nontraumatic Hypotension and Shock in the Emergency Department and Prehospital Setting Prevalence, Etiology and Mortality:
More informationGranisetron Kabi, 1mg/ml, concentrate for solution for injection/infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Granisetron Kabi, 1mg/ml, concentrate for solution for injection/infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains granisetron
More informationSUMMARY OF PRODUCT CHARACTERISTICS
Page 1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Sinora 1 mg/ml concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml concentrate for solution
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Page 1 of 7
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 7 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Prilocard 5mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationSepsis is an important issue. Clinician s decision-making capability. Guideline recommendations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Clinicians decision-making capability Guideline recommendations Sepsis is an important issue 8.7%
More informationFluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE
Fluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE In critically ill patients: too little fluid Low preload,
More information1. What Dobutamine 12.5 mg/ml is and what it is used for
Labelling and Package Leaflet page 1/14 1.3.5 Package Leaflet PACKAGE LEAFLET: INFORMATION FOR THE USER, concentrate for solution for infusion Active substance: dobutamine Read all of this leaflet carefully
More informationRenal physiology D.HAMMOUDI.MD
Renal physiology D.HAMMOUDI.MD Functions Regulating blood ionic composition Regulating blood ph Regulating blood volume Regulating blood pressure Produce calcitrol and erythropoietin Regulating blood glucose
More informationPediatric Sepsis Treatment:
Disclosures Pediatric Sepsis Treatment: (treat) Early & (reevaluate) Often None June 11, 2018 Leslie Dervan, MD MS Pacific Northwest Sepsis Conference 1 Agenda Sepsis: pathophysiology at-a-glance Pediatric
More informationCardiovascular System B L O O D V E S S E L S 2
Cardiovascular System B L O O D V E S S E L S 2 Blood Pressure Main factors influencing blood pressure: Cardiac output (CO) Peripheral resistance (PR) Blood volume Peripheral resistance is a major factor
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Synacthen 250 micrograms/ml solution for injection. Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance 250 micrograms of Tetracosactide.
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationBlood Pressure Regulation Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.
Blood Pressure Regulation Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (http://www.aw-bc.com) Page 1. Introduction There are two basic mechanisms for regulating
More informationWhat would be the response of the sympathetic system to this patient s decrease in arterial pressure?
CASE 51 A 62-year-old man undergoes surgery to correct a herniated disc in his spine. The patient is thought to have an uncomplicated surgery until he complains of extreme abdominal distention and pain
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Citanest with Octapressin Dental 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Prilocaine Hydrochloride 30 mg (54 mg/1.8
More informationBuserelin animedica mg/ml Injektionslösung für Rinder, Pferde, Kaninchen
1. NAME OF THE VETERINARY MEDICINAL PRODUCT Buserelin animedica 0,004 mg/ml Injektionslösung für Rinder, Pferde, Kaninchen (Germany) Buserelin animedica 0.004 mg/ml Injektionslösung für Rinder, Pferde,
More informationSurviving Sepsis Campaign Guidelines 2012 & Update for David E. Tannehill, DO Critical Care Medicine Mercy Hospital St.
Surviving Sepsis Campaign Guidelines 2012 & Update for 2015 David E. Tannehill, DO Critical Care Medicine Mercy Hospital St. Louis Be appropriately aggressive the longer one delays aggressive metabolic
More information6/5/2014. Sepsis Management and Hemodynamics. 2004: International group of experts,
Sepsis Management and Hemodynamics Javier Perez-Fernandez, M.D., F.C.C.P. Medical Director Critical Care Services, Baptist t Hospital of Miamii Medical Director Pulmonary Services, West Kendall Baptist
More informationSHOCK. Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital
SHOCK Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital 1 Definition Shock is an acute, complex state of circulatory dysfunction
More informationRenal-Related Questions
Renal-Related Questions 1) List the major segments of the nephron and for each segment describe in a single sentence what happens to sodium there. (10 points). 2) a) Describe the handling by the nephron
More informationARGININE VASOPRESSIN (AVP)
ARGININE VASOPRESSIN (AVP) AFFECTS BLOOD PRESSURE AND RENAL WATER REABSORPTION WHAT ELSE DOES IT DO? Michael F. Michelis, M.D., F.A.C.P., F.A.S.N. Director, Division of Nephrology Lenox Hill Hospital,
More informationNE refractoriness: From Definition To Treatment... Prof. Alain Combes
NE refractoriness: From Definition To Treatment... Prof. Alain Combes Service de Réanimation ican, Institute of Cardiometabolism and Nutrition Hôpital Pitié-Salpêtrière, AP-HP, Paris Université Pierre
More information1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1. NAME OF THE MEDICINAL PRODUCT Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Oxymetazoline hydrochloride 0.5 mg/ml 1 spray (50 l) contains approximately 25
More informationSepsis and Hemodynamic Support in September 15, 2017 Carleen Risaliti
Sepsis and Hemodynamic Support in 2017 September 15, 2017 Carleen Risaliti Objectives Review fluid resuscitation guidelines in septic shock Discuss volume assessment v. fluid responsiveness Evaluate pros
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT DigiFab, 40 mg/vial digoxin immune Fab, Powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each glass vial
More informationEffects of combined vasopressin-noradrenaline in pediatric patients with refractory septic shock
Effects of combined vasopressin-noradrenaline in pediatric patients with refractory septic shock J. A. Fernandez 1, A. C. Sepúlveda 2, M. Salas 2, PA Lopez 3, S. J. Olarte 2 1 Pediatric Critical Care Department,
More informationPharmacology of inotropes and vasopressors
Pharmacology of inotropes and vasopressors Curriculum 3.3 Recognises and manages the patient with circulatory failure 4.4 Uses fluids and vasoactive / inotropic drugs to support the circulation PR_BK_41
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Synthamin 14, 8.5% Amino Acid Intravenous Infusion
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Synthamin 14, 8.5% Amino Acid Intravenous Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION L-Leucine Ph. Eur 0.620% w/v L-Isoleucine
More informationMonday, 17 April 2017 BODY FLUID HOMEOSTASIS
Monday, 17 April 2017 BODY FLUID HOMEOSTASIS Phenomenon: shipwrecked sailor on raft in ocean ("water, water everywhere but not a drop to drink") Why are the sailors thirsty? (What stimulated thirst?) Why
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationPACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Dobutamine 12.5mg/ml Concentrate for Solution for Infusion Dobutamine Hydrochloride
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Dobutamine 12.5mg/ml Concentrate for Solution for Infusion Dobutamine Hydrochloride Read all of this leaflet carefully before you start using this medicine
More information